261 related articles for article (PubMed ID: 32715375)
1. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
[TBL] [Abstract][Full Text] [Related]
3. Use of tocilizumab in amyloid a nephropathy associated with Sweet syndrome: a case report and literature review.
Giannese D; Ferro F; Moriconi D; Bonadio AG; Elefante E; Egidi MF; Cupisti A; Baldini C
CEN Case Rep; 2021 Feb; 10(1):23-29. PubMed ID: 32681397
[TBL] [Abstract][Full Text] [Related]
4. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.
Tosaki T; Okabe M; Suzuki T; Shimizu A; Koike K; Tsuboi N; Kawamura T; Ohashi R; Yano S; Yokoo T
CEN Case Rep; 2021 May; 10(2):265-272. PubMed ID: 33389670
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
[TBL] [Abstract][Full Text] [Related]
6. Membranous Nephropathy Associated With Multicentric Castleman Disease-Efficacy of Interleukin 6 Antibody for Nephrotic Syndrome.
Horino T; Kashio T; Inotani S; Ishihara M; Ichii O
J Clin Rheumatol; 2022 Jan; 28(1):e1-e2. PubMed ID: 34897198
[No Abstract] [Full Text] [Related]
7. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
8. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature.
Zhou Q; Zhang Y; Zhou G; Zhu J
BMC Nephrol; 2020 Nov; 21(1):499. PubMed ID: 33225930
[TBL] [Abstract][Full Text] [Related]
9. Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series.
Kojima D; Yamaguchi S; Hashiguchi A; Hayashi K; Uchiyama K; Yoshimoto N; Adachi K; Nakayama T; Nishioka K; Tajima T; Morimoto K; Yoshino J; Yoshida T; Monkawa T; Kanda T; Itoh H
Front Med (Lausanne); 2022; 9():1037032. PubMed ID: 36698794
[TBL] [Abstract][Full Text] [Related]
10. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab.
Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
[No Abstract] [Full Text] [Related]
13. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T
Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389
[TBL] [Abstract][Full Text] [Related]
14. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
Galeotti C; Boucheron A; Guillaume S; Koné-Paut I
Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
[TBL] [Abstract][Full Text] [Related]
15. Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease.
Togitani K; Ogasawara F; Arakawa Y; Sugimura N; Miyazaki R; Kojima K
Intern Med; 2023 Feb; 62(3):449-452. PubMed ID: 35732449
[TBL] [Abstract][Full Text] [Related]
16. Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
Turcotte LM; Correll CK; Reed RC; Moertel CL
Pediatr Blood Cancer; 2014 Apr; 61(4):737-9. PubMed ID: 24019247
[TBL] [Abstract][Full Text] [Related]
17. Remission of nephrotic syndrome due to AA-amyloidosis, complicating familiar Mediterranean fever, with tocilizumab.
Serelis J; Christaki S; Skopouli FN
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S169. PubMed ID: 25572486
[No Abstract] [Full Text] [Related]
18. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
[TBL] [Abstract][Full Text] [Related]
19. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
20. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
